Joseph M. PariseAssociateMcDermott Will & Emery Websitewww.mwe.comOrganization ProfileFull ProfileBlogwww.mwe.com/insightsConnectEmailTwitterLinkedIn212 547 5411 Professional Biography Joseph M. Parise is an associate in the law firm of McDermott Will & Emery LLP and is based in the Firm’s New York office. He focuses his practice on general health matters. More Legal and Business Bylines From Joseph M. Parise New York Proposes Regulatory Review of Physician Practice Transactions - (Posted On Friday, February 17, 2023) Massachusetts Enacts Legislation Promoting Access to Quality and Affordable Care, Telehealth - (Posted On Monday, February 08, 2021) The Practical Import of the Carothers Decision on New York Practice Management Arrangements - (Posted On Wednesday, April 19, 2017) Final Rules Released Covering 340B Ceiling Prices and Manufacturer Penalties - (Posted On Thursday, January 12, 2017) HHS Proposes Administrative Dispute Resolution Process for 340B-Related Claims - (Posted On Tuesday, August 16, 2016) OIG Reports on, Proposes Alternatives to Medicare Part B Reimbursement for 340B Drugs - (Posted On Monday, December 07, 2015) D.C. Federal Court Rejects HHS Interpretation of 340B Program’s Orphan Drug Rule - (Posted On Tuesday, October 20, 2015) Proposed Rules Released Covering 340B Ceiling Prices and Manufacturer Penalties - (Posted On Wednesday, June 17, 2015) House Subcommittee Circulates Proposed Legislation Providing Insight on the Future of the 340B Drug Pricing Program - (Posted On Tuesday, May 26, 2015) 340B ‘Mega-Guidance’ Arrives at Office of Management and Budget - (Posted On Thursday, May 07, 2015) Pagination Page 1 Next page Next › Current Legal Analysis Scrutiny on Financial Institutions Compliance Expected to Increase During Trump Administration by: Mark D. Nelson President Trump’s Executive Orders on Immigration and What They Mean for Employers by: Otieno B. Ombok , Amy L. Peck US Treasury and IRS Unveil Proposed Regulations for Commercial EV Tax Credit, Sparking Questions on Recapture Provisions by: Chris DiAngelo , Brandon D. Hadley At Long Last, DEA’s Remote Prescribing Rules 2.0 Are (Really) Here! (Pending Further Consideration by the Incoming Administration . . .) by: Alan J. Arville , Audrey Davis The TikTok Ban Saga: SCOTUS, Trump’s Executive Order, and the Implications for Digital Marketing and Emerging Platforms by: Jeffrey M. Kelly FTC Announces Significant Increases to the 2025 HSR Reporting Thresholds by: Carrie A. Hanger , Colleen Pleasant Kline New TTB Standard of Fill No Place for Kegged Cocktails by: Benjamin Sheppard 60-Second Sustains: The Mission Essential Group by: Elizabeth N. Jochum , David L. Bodner Upcoming Events Jan 22 2025 Employee Activism and the Issues It Can Create Jan 22 2025 The SEC under President Trump: A Preview Jan 22 2025 Transgender Employees and Related Issues in the Workplace Jan 28 2025 Antibody Drug Conjugates Keep Growing: What You Need to Know Print
